SCHEMBL31516637

SCHEMBL31516637

COc1cc(C(=O)N[S@](=N)(=O)c2c(OC)ccc(Cl)c2OC)ccc1Cn1cccn1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KAT7 O95251 10/20 0.41
▸ KAT6A Q92794 10/20 0.41
▸ KAT6B Q8WYB5 6/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ NPSR1 Q6W5P4 2/20 0.41
▸ GAA P10253 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ HDAC8 Q9BY41 3/20 0.41
▸ HDAC6 Q9UBN7 2/20 0.39
▸ HDAC1 Q13547 1/20 0.39
▸ KLKB1 P03952 1/20 0.39
▸ SCN9A Q15858 1/20 0.39
▸ KAT5 Q92993 4/20 0.39
▸ KAT8 Q9H7Z6 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31516750 1.00 KAT7 (0.41) KAT7KAT6AKAT6BMEN1KMT2A
SCHEMBL31516651 0.91 KAT7 (0.44) KAT7KAT6AKAT6BMEN1KMT2A
SCHEMBL31516703 0.91 KAT7 (0.42) KAT7KAT6AKAT6BMEN1KMT2A
SCHEMBL31516687 0.91 KAT7 (0.42) KAT7KAT6AKAT6BMEN1KMT2A
SCHEMBL31516615 0.89 KAT6A (0.49) KAT7KAT6AKAT6BHDAC6HDAC1
SCHEMBL31516684 0.89 KAT6A (0.49) KAT7KAT6AKAT6BHDAC6HDAC1
SCHEMBL31516634 0.89 KAT6A (0.49) KAT7KAT6AKAT6BHDAC6HDAC1
SCHEMBL31516725 0.85 KAT7 (0.43) KAT7KAT6AKAT6BGAAHTT
SCHEMBL31516676 0.85 KAT7 (0.43) KAT7KAT6AKAT6BGAAHTT
SCHEMBL31516733 0.85 KAT7 (0.43) KAT7KAT6AKAT6BGAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS INC (US) 2026-01-15 — — US disclosed
US-12428379-B2 Acylsulfonamide KAT6A inhibitors OLEMA PHARMACEUTICALS, INC. (US) 2025-09-30 — — US disclosed
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. 2025-05-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B KAT7 5/4885KAT6A 1/4885KAT6B 3/4885
US-12428379-B2 Acylsulfonamide KAT6A inhibitors KAT6A, KAT2A, KAT6B KAT7 5/4885KAT6A 1/4885KAT6B 3/4885
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B KAT7 4/4885KAT6A 1/4885KAT6B 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback